Categories Analysis, Health Care

SmileDirectClub (SDC) bets on rapid telemedicine-adoption to drive growth

Recently, SmileDirectClub commenced operations in Mexico, marking its entry into Latin America

The adoption of telemedicine accelerated in recent months, especially after the pandemic-related shelter-in-place orders came into effect. The trend will likely continue even after the crisis subsides, thanks to the ongoing innovations in that area and the convenience it offers to both patients and caregivers. SmileDirectClub, Inc. (NASDAQ: SDC), an emerging teledentistry company, registered sequential revenue growth in each of the trailing four quarters, after recovering from the initial slowdown.

Profitability

The Tennessee-based oral care company is yet to generate profit, after going public more than a year ago. On the positive side, the bottom-line numbers came in above analysts’ forecast in recent quarters. Taking a cue from the growing adoption of remote medical care, analysts in general recommend investing in the company’s stock, which according to them would grow double digits in the next twelve months. However, the lackluster performance of the stock, which has been witnessing significant insider activity, shows investors are cautious.

From SmileDirectClub’s Q1 2021 earnings conference call:

On growth, we are making good progress against our initiatives. And excluding the impact of the cyberattack in Q2, we’re executing against our long-term revenue growth targets. On cost, we saw continued gross margin expansion in the quarter, enabled by our manufacturing initiatives. This, in combination with our sales and marketing efficiency and our continued cost discipline across the business, puts us well on our way to achieving our long-term targets. Since the enactment of our control growth plan in Q4 of 2019, we have completely reset the cost profile of the business.

SmileDirectClub Q1 2021 earnings infographic

Bullish Outlook

SmileDirectClub’s executives look to expand the customer base by leveraging the company’s competitive prices and by offering a better customer experience. Currently, they are targetting annual average revenue growth of 20-30% for the next five years. Meanwhile, the ongoing investments in international expansion and the high costs related to customer acquisition are expected to affect the company’s turnaround plan. Recently, SmileDirectClub commenced operations in Mexico, marking its entry into Latin America.


Read management/analysts comments on SmileDirectClub’s Q1 report


The company offers doctor-directed digital end-to-end experience in teledentistry, with round-the-clock access to orthodontic care. In the first quarter, net loss narrowed slightly to $0.25 per share but missed Wall Street’s prediction. Revenues edged up 1% to a record high of about $200 million as an uptick in the core business was nearly offset by weakness in the financing segment.

Earlier this year, operations were disrupted by a cyberattack that raised concerns about the safety of the digital platform. While timely intervention averted further damages, costs related to the recovery process affected the company’s financial performance.

At the Bourses

SmileDirectClub’s stock is yet to bounce back from the post-IPO slump of September 2019, though it has recovered from last year’s record lows. The shares slipped into the single-digit territory recently and lost further after Monday’s earnings report.

Most Popular

Context Therapeutics: Another clinical-stage oncology research firm to go public soon

The US primary markets seem to be having a record-breaking start to the year, with over $171 billion raised in the first half of 2021 compared to $168 billion for

Biogen (BIIB) Stock: Does FDA nod for Aduhelm offer a buying opportunity?

The pharmaceutical industry has been witnessing hectic activity for some time, with most drug makers either channelizing their resources for vaccine development or engaging in COVID care programs. Biotechnology giant

IPO News: Monte Rosa Therapeutics will go public this week, here are a few things to know

Biotechnology company Monte Rosa Therapeutics is slated to go public this week. In a pandemic-ridden world, this industry is expanding at a healthy pace. The global biotechnology market is estimated

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top